ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Tectonic Therapeutic has raised $80 million in series A financing for G-protein-coupled receptor (GPCR) drug discovery. The Watertown, Massachusetts–based start-up was cofounded in 2019 by Andrew Kruse and Timothy Springer, both professors in Harvard Medical School’s Department of Biological Chemistry and Molecular Pharmacology. Springer has founded multiple biotech companies, was a founding investor in Moderna, and invested in the series A round. Tectonic will use technology developed by Kruse to target currently undruggable GPCRs for undisclosed conditions.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter